Accordingly, routine evaluation of PD-L1 expression on TAMs serves not only as a prognostic biomarker but also as a predictive indicator for responsiveness to PD-1 blockade therapies in NSCLC (133). This evidence concerns the gene CD274 and non-small cell lung carcinoma.